Popular Trials
Cell Therapy
NT-501 Cell Therapy for Glaucoma
Recruiting0 awardsPhase 2
Palo Alto, California
This trial tests tiny devices that release a protective protein into the eyes of patients with glaucoma-related vision problems. The protein helps protect nerve cells, potentially preventing further vision loss and improving sight.
Cell Therapy
NT-501 ECT Implant for Glaucoma
Recruiting0 awardsPhase 2
Palo Alto, California
This trial tests a new eye implant called NT-501 for people with glaucoma. The implant releases medicine directly into the eye to help protect it from damage. It aims to help those who may not respond well to usual treatments. An earlier version of this implant has been used to help manage glaucoma in patients who did not benefit from other treatments.
Popular Filters
Trials for Open-Angle Glaucoma Patients
Lumify for Glaucoma Side Effects
Recruiting2 awardsPhase 4
New Orleans, Louisiana
This trial is testing Lumify™ eye drops, which help reduce eye redness, in glaucoma patients who are already using Brimonidine eye drops. These patients often have red eyes as a side effect of their current treatment. Lumify™ works by making the blood vessels in the eyes smaller, which helps to reduce redness.
Electrical Stimulation
Electrical Stimulation for Glaucoma
Recruiting0 awards
Palo Alto, California
This trial is testing if using a home device that sends small electrical pulses to the eyes can help treat open-angle glaucoma. This condition causes eye nerves to die off quickly, and the study aims to see if this new method is safe and effective.
Device
Electrical Stimulation for Glaucoma
Recruiting1 award
Palo Alto, California
This trial is testing if using a home device that sends small electrical pulses to the eye can help treat open-angle glaucoma. It focuses on patients who are safe for this treatment but don't fit other trial criteria. The electrical pulses might help protect the eye nerves.
Device
Hydrus Microstent vs Goniotomy for Glaucoma
Recruiting1 award5 criteria
Boston, Massachusetts
This trial aims to compare the effectiveness and safety of three different minimally invasive surgeries for glaucoma when done alongside cataract surgery. The main questions it seeks to answer are how well each surgery
Trials for OAG Patients
Lumify for Glaucoma Side Effects
Recruiting2 awardsPhase 4
New Orleans, Louisiana
This trial is testing Lumify™ eye drops, which help reduce eye redness, in glaucoma patients who are already using Brimonidine eye drops. These patients often have red eyes as a side effect of their current treatment. Lumify™ works by making the blood vessels in the eyes smaller, which helps to reduce redness.
Electrical Stimulation
Electrical Stimulation for Glaucoma
Recruiting0 awards
Palo Alto, California
This trial is testing if using a home device that sends small electrical pulses to the eyes can help treat open-angle glaucoma. This condition causes eye nerves to die off quickly, and the study aims to see if this new method is safe and effective.
Device
Electrical Stimulation for Glaucoma
Recruiting1 award
Palo Alto, California
This trial is testing if using a home device that sends small electrical pulses to the eye can help treat open-angle glaucoma. It focuses on patients who are safe for this treatment but don't fit other trial criteria. The electrical pulses might help protect the eye nerves.
Device
Hydrus Microstent vs Goniotomy for Glaucoma
Recruiting1 award5 criteria
Boston, Massachusetts
This trial aims to compare the effectiveness and safety of three different minimally invasive surgeries for glaucoma when done alongside cataract surgery. The main questions it seeks to answer are how well each surgery
Phase 3 Trials
Prostaglandin Analog
Bimatoprost SR for Glaucoma
Recruiting2 awardsPhase 3
Sun City, Arizona
This trial tests a long-lasting eye medication called Bimatoprost SR. It is for people with certain eye conditions who can't use regular eye drops effectively. The medication works by helping fluid drain from the eye, reducing pressure. Bimatoprost has been widely used for glaucoma management, typically delivered via eye drops, but newer methods like sustained-release implants are being explored to improve efficiency.
Prostaglandin Analog
NCX 470 for Glaucoma
Recruiting2 awardsPhase 3
Newport Beach, California
This trial is testing NCX 470 eye drops to see if they can safely and effectively lower eye pressure in people with high eye pressure or glaucoma. The goal is to protect their vision by reducing the pressure inside their eyes. NCX 470 is a nitric oxide (NO)-donating bimatoprost with clinically demonstrated pressure-lowering effects.
Trials With No Placebo
Laser Treatment for Glaucoma Prevention in Corneal Disease
Recruiting1 award
Montreal, Quebec
This trial is studying whether a laser treatment can help prevent glaucoma in patients receiving a Boston keratoprosthesis, a device used to restore vision in patients who have failed traditional corneal transplants.
Cannabinoid
Medical Cannabis for Chronic Pain
Recruiting1 awardPhase 2
Boca Raton, Florida
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Stem Cell Therapy
Stem Cell Therapy for Retinal and Optic Nerve Disorders
Recruiting1 award8 criteria
Westport, Connecticut
This trial will use stem cells from patients' own bone marrow to treat severe vision loss caused by retinal or optic nerve damage. The stem cells will be injected into the eye to help repair the damaged tissues. SCOTS is the largest ophthalmology stem cell study registered at the National Institutes of Health, using autologous bone marrow-derived stem cells for retinal and optic nerve diseases.
Procedure
GDD Timing with Boston KPro for Glaucoma
Recruiting1 award5 criteria
Montreal, Quebec
This trial will help surgeons to determine whether it is better to implant a glaucoma drainage device (GDD) at the time of the Boston KPro surgery or 6 months later, in the prevention of the progression of glaucoma.
Device
Electrical Stimulation for Glaucoma
Recruiting1 award
Palo Alto, California
This trial is testing if using a home device that sends small electrical pulses to the eye can help treat open-angle glaucoma. It focuses on patients who are safe for this treatment but don't fit other trial criteria. The electrical pulses might help protect the eye nerves.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.